RxDoctor Payments Data

Nicholas Lemley, DO

Family Medicine · Cuero, TXNPI 1457885592

Payments from drug & device makers

$1,394in general payments, 2019–2025

Across 83 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$162
  • Merck$129
  • Boehringer Ingelheim$102
  • Otsuka America Pharmaceutical, Inc.$90
  • Novo Nordisk$64
  • Intuitive Surgical$63
  • plus $784 from 28 others

What the payments were for

  • Food & beverage$1,394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,394 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$5,589
Medicare patients
80
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide110$113,054
OzempicSemaglutide100$102,072
JardianceEmpagliflozin192$97,520
EliquisApixaban245$83,045
FarxigaDapagliflozin Propanediol61$38,217
TrulicityDulaglutide26$23,548
Invega SustennaPaliperidone Palmitate14$23,250
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$20,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$20,888
RexultiBrexpiprazole25$18,139
RybelsusSemaglutide17$17,952
EntrestoSacubitril/Valsartan45$15,087
VascepaIcosapent Ethyl44$15,040
XareltoRivaroxaban14$11,582
Potassium Chloride439$11,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$44$136,602136 claims
Novo NordiskOzempic, Rybelsus$64$120,025117 claims
Boehringer IngelheimJardiance, Tradjenta$102$107,159216 claims
AstraZenecaFarxiga, Breztri Aerosphere$56$46,24374 claims
GSKTrelegy Ellipta$57$20,88832 claims
Otsuka America Pharmaceutical, Inc.Rexulti$90$18,13925 claims
MerckJanuvia, Belsomra$129$15,37737 claims
NovartisEntresto$19$15,08745 claims
Astellas Pharma US IncMyrbetriq$14$10,21136 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cuero

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →